Change You Can Bayh
- October 29th, 2009
- Write comment
Senator Evan Bayh (D-IN) recently told reporters that he would reserve the right to join Republicans in their Filibuster of the Democratic Health Care Bill if there is a strong “Public Option”. This announcement comes as Research 2000 released a poll that showed 52 percent of Indiana voters back a Public Option. Why would Senator Bayh stand in the way of his own party’s agenda? Here are some FACTS about Sen. Bayh and his wife Susan: -Senator Bayh has taken more than 1.5 million dollars in campaign contributions from insurance companies. -Susan Bayh was a corporate lawyer for the Eli Lilly’s Phamaceutical division from 1989-1994 -Susan Bayh has been a Director of Nastech Pharmaceutical Co. Inc., since May 25, 2005. -Susan Bayh served as a Director of Cubist Pharmaceuticals Inc., from June 2000 to September 29, 2004 -Susan Bayh served as a Director of Anthem Insurance Companies Inc., (subsidiary of WellPoint Inc) from 1998 to May 2003. This list is actually an abbreviated version of how the tentacles of corporate greed have infected the Bayh Family. The thing that they do not understand is poverty. Has Senator Bayh or his wife ever had to choose between paying bills or buying groceries? Has Senator Bayh and his wife ever sacrificed their health because of an inability to afford medical treatment? Has Senator Bayh and his wife ever known anything other than privilege, financial security, and unfettered income potential? No, they have not. Do your part and contact Senator Evan Bayh to demand a public option. Here is the message I sent to Senator Bayh: Sen. Bayh, I was disgusted to hear that you were willing to support a filibuster against the Democratic Health Care Bill because of your opposition to the Public Option. Considering the fact that your wife sits on the board of Wellpoint and your own political contributions from the industry, you can no longer be trusted to represent the people of Indiana. I am looking forward to voting for your Democratic Primary challenger in 2010.
